Initial experience with the cardiva Boomerang™ vascular closure device in diagnostic catheterization

Doyle, Brendan; Godfrey, Michael; Lennon, Ryan J.; Ryan, James L.; Bresnahan, John F.; Rihal, Charanjit S.; Ting, Henry H.

doi:10.1002/ccd.20937

Cited by 30 publications

(17 citation statements)

References 56 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 The Boomerang assisted-compression system (Cardiva Medical, Inc, Mountain View, Calif) has been studied in 96 consecutive patients undergoing diagnostic cardiac catheterization, with successful deployment in 99% of patients without any major complications in the study cohort. 43 The D-Stat dry patch (Vascular Solutions, Minneapolis, Minn) was compared with manual compression in a multicenter randomized trial of 376 patients undergoing diagnostic or peripheral angiography. 47 Although time to ambulation was slightly shorter (392 versus 415 minutes, Pϭ0.02), there were no differences in time to discharge or vascular complications.…”

Section: Evidence For Passive-closure Devicesmentioning

confidence: 99%

Arteriotomy Closure Devices for Cardiovascular Procedures

Patel¹,

Jneid²,

Derdeyn³

et al. 2010

Circulation

137

View full text Add to dashboard Cite

Section: Evidence For Passive-closure Devicesmentioning

confidence: 99%

Arteriotomy Closure Devices for Cardiovascular Procedures

Patel¹,

Jneid²,

Derdeyn³

et al. 2010

Circulation

137

View full text Add to dashboard Cite

“…"Passive closure" technologies have been developed in parallel with the active closure devices. Passive closure approaches have focused on enhanced manual compression utilizing external patches with prothrombotic coatings (Syvek Patch, Marine Polymer Technologies, Danvers, Massachusetts) (11,12), wire-stimulated track thrombosis (Boomerang Wire, Cardiva Medical, Mountainview, California) (13), or assisted compression with mechanical clamps; the passive closure devices do not afford immediate (Ͻ5 min) hemostasis (14,15) (Fig. 2).…”

Section: Vcds: the First Decadementioning

confidence: 99%

Vascular Closure Devices

Dauerman

Applegate

Cohen

2007

Journal of the American College of Cardiology

171

123

View full text Add to dashboard Cite

Vascular closure devices (VCDs) introduce a novel means for improving patient comfort and accelerating ambulation after invasive cardiovascular procedures performed via femoral arterial access. Vascular closure devices have provided simple, rapid, and reliable hemostasis in a variety of clinical settings. Despite more than a decade of development, however, VCD utilization has neither been routine in the U.S. nor around the world. Their limited adoption reflects concerns of higher costs for cardiac procedures and a lack of data confirming a significant reduction in vascular complications compared with manual compression. Recent data, however, suggest that VCD are improving, complication rates associated with their use may be decreasing, and their utilization may improve the process of care after femoral artery access. Challenges in the second decade of VCD experience will include performing definitive randomized trials, evaluating outcomes in higher-risk patients, and developing more ideal closure devices.

show abstract

“…A recent study cited an impressive success rate of 99% in achieving complete hemostasis with an average time of 82 minutes from the end of device application to ambulation. 23 However, the need for manual compression following the device application represents a potential drawback of this particular device.…”

Section: Metal Clip or Disc-based Vascular Closure Devicementioning

confidence: 99%

Access site management with vascular closure devices for percutaneous transarterial procedures

Bechara

Annambhotla

Lin

2010

Journal of Vascular Surgery

View full text Add to dashboard Cite

The rising numbers in the aging population will undoubtedly lead to a corresponding increase in percutaneous endovascular procedures to address their cardiovascular health issues. With a constant drive to develop innovative treatment methods to achieve improved treatment outcomes while reducing procedural-related complications, endovascular interventionalists have focused on technologies to provide efficient hemostatic control of femoral artery access following percutaneous diagnostic or therapeutic angiographic procedures. Compared with the traditional hemostatic method using manual compression, several arterial closure devices (ACD) have been shown to reduce time of hemostasis, enable early patient ambulation, reduce hospitalization staff use, and improve patient outcome. However, these ACDs have their shortcomings as the interventionalists need to be familiar with these technologies as well as their potential complications. This article provides a comprehensive review of current closure device technologies as well as clinical experiences with these devices. The adjunctive role of these technologies in endovascular aortic aneurysm repair is also discussed.

show abstract

Initial experience with the cardiva Boomerang™ vascular closure device in diagnostic catheterization

Abstract: The Cardiva Boomerang device is safe and effective in patients undergoing diagnostic cardiac catheterization using the transfemoral approach, facilitating early ambulation with low rates of vascular complications.

Cited by 30 publications

References 56 publications

Arteriotomy Closure Devices for Cardiovascular Procedures

Arteriotomy Closure Devices for Cardiovascular Procedures

Vascular Closure Devices

Access site management with vascular closure devices for percutaneous transarterial procedures

Contact Info

Product

Resources

About